A useful way to understand Capecitabine is to start with the biology it targets. Converted preferentially in tissues to 5-FU, producing antimetabolite effects on thymidylate synthase and RNA/DNA synthesis. The drug interferes with nucleotide metabolism or related cellular pathways, limiting the ability of actively dividing tumor cells to synthesize or process essential DNA building blocks. The database classifies it as Chemotherapy; Antimetabolite and associates it with Colorectal; Breast; Gastric; Gastroesophageal Junction. Its principal oncology indications are Colorectal cancer; breast cancer; gastric/GEJ and other fluoropyrimidine-sensitive cancers. Depending on the disease, the agent may appear as a single-agent treatment, a component of combination therapy, or part of a defined treatment sequence. The documented regimen examples are CAPOX/XELOX; CAPOX + bevacizumab; capecitabine + oxaliplatin or other disease-specific combinations. Its clinical role is defined by the disease-specific regimen, treatment intent, and patient-selection criteria associated with the listed indications. This distinction matters because treatment selection is not determined simply by the presence of a cancer diagnosis; the tumor subtype, disease stage, previous therapy, and molecular or receptor characteristics can narrow the appropriate setting. The pharmacology helps explain its individual position among related medicines. This description summarizes the supplied clinical information without giving individualized dosing or treatment instructions. Current labeling and the applicable oncology guideline should be consulted when the database is used for clinical reference.